The global lixisenatide market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Lixisenatide is a receptor agonist used for the treatment of type 2 diabetes. The drug controls blood sugar levels by increasing insulin levels in the blood, which reduces body absorption of sugar. The rising prevalence of diabetes is contributing to the growth of the market. According to the IDF (International Diabetes Federation), there were 463 million diabetics globally in 2020, with Type 2 diabetes accounting for the vast majority (around 90%) of cases.

However, the presence of alternatives to treat diabetes is restraining the growth of the global lixisenatide market. For instance, in July 2021, Viatris and Biocon Biologics have received the US Food and Drug Administration (FDA) approval of Semglee for the treatment of diabetes. Semglee is an interchangeable biosimilar product indicated to improve glycemic control in adults and pediatric patients with type -1 diabetes mellitus and adults with type-2 diabetes mellitus. FDA further stated that approval of these insulin products can provide patients with additional safe, high quality, and cost-effective options for treating diabetes.

Impact of COVID-19 Pandemic on Global Lixisenatide Market 

The COVID-19 pandemic has resulted in a significant impact on the global lixisenatide market. The regulations such as social distancing minimized staff and minimized hours for operating clinics and medical centers have resulted in a negative impact on the global lixisenatide market. Moreover, delayed business deals and disruption in the supply chain due to restrictions and lockdowns resulted as a major factor in declining the growth of the global lixisenatide market. However, the unwillingness of people to visit healthcare facilities due to the fear of getting infected also added to the declining factor.

Segmental Outlook

The global lixisenatide market is segmented based on type and application. Based on the type the lixisenatide market is further sub-segmented into tablets and liquid injections. Based on the application, the market is further sub-segmented into hospitals, clinics, medical centers, and others. Among these, the tablet segment is anticipated to hold a major share in the market owing to the rise in research and development activities coupled with new product launches.?

Global Lixisenatide Market by Application, 2021 (%) 

Hospital Segment is Anticipated to Hold a Prominent Share in the Global Lixisenatide Market 

The hospital segment is anticipated to hold a prominent share in the market owing to the rise in hospital visits due to diabetes. For instance, according to the data published by National Center for Biotechnology Information (NCBI) in 2020, people with diabetes have a 35% chance of referral for elective operations and a greater chance of hospitalization compared to those without diabetes. Moreover, 30% of people, with a post-discharge diagnosis of diabetes are anticipated to require 2 or more hospitalizations in any given year. Furthermore, according to the National Diabetes Inpatient Audit, the prevalence of diabetes among inpatients has risen to 20% in 2019. In addition, people hospitalized with a diagnosis for diabetes are anticipated to stay longer in the hospital than those without a diagnosis of diabetes admitted for the same condition. Thus, the rise in the prevalence of hospital visits is anticipated to drive the growth of the hospital segment, further accelerating the growth of the global lixisenatide market.

Regional Outlook 

The global lixisenatide market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement. Among these, Asia –the Pacific region is anticipated to hold a considerable share in the market owing to the rise in awareness campaigns regarding prevention of diabetes.

Global Lixisenatide Market, by Region 2022-2028 

North America Region is Anticipated to Hold Prominent Share in the Global Lixisenatide Market 

The North American region is anticipated to hold a prominent share in the market owing to the rise in the prevalence of diabetes. For instance, according to the data published by CDC’s National Diabetes Statistics Report for 2019, 37.3 million Americans, or 11.3% of the total US population suffered from diabetes out of which 1.9 million Americans were identified with type 1 diabetes including about 244,000 children and adults. Further, of the 37.3 million diabetic patients,28.7 million were diagnosed and 8.5 million were undiagnosed. However, the rise in the prevalence of pre diabetes is one of the major factors driving the lixisenatide market in the region.

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), prediabetes is a health condition wherein the blood sugar levels are higher than normal and are associated with a greater risk of developing type 2 diabetes. For instance, according to CDC’s National Diabetes Statistics Report 2020, approximately 88 million or 34.5% of U.S adults have prediabetes. Thus, the rise in the prevalence of diabetes is anticipated to drive the growth of the market in the region, during the forecast period.

Market Players Outlook 

The major players serving the global lixisenatide market are Zealand Pharma, Sanofi Aventis U.S Llc, Elli Lily & Co, GlaxoSmithKline Plc.,and more among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2019, the US Food and Drug Administration (FDA) has approved the expanded use of Sanofi’s Soliqua 100/33 (insulin glargine and lixisenatide injection). The FDA approval was based on the data from the LixiLan-O-Clinical trial, which showed that the treatment with Soliqua 100/33 led to a significant reduction in blood sugar level in individuals associated with type-2 diabetes.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global lixisenatide market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.